To understand the disease mechanisms at work in ALS, our first objective was to perform clinical research and study the natural disease course of ALS. This strategy led to the first successful clinical trial in 1994. Beside our current involvement with clinical trials, we acquired an expertise in muscle biomarkers, genetics and neuroimaging.
Contact
LocationHôpital de la Salpêtrière, Boulevard de l'Hopital, Paris, France
Contact
Specialists
Current trials
In preparation
Phase iii
The Lighthouse 2 trial
Investigator initiated trial
The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.
In preparation
Phase iii
MAGNET
Platform trial
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
Recruiting
Phase iii
TUDCA-ALS (TUDCA)
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.